세계의 기립성 저혈압 치료제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 제품 유형별, 진단 검사 유형별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)
Orthostatic Hypotension Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Diagnostics Test Type, By End User, By Region & Competition, 2020-2030F
세계의 기립성 저혈압 치료제 시장은 2024년 5억 4,226만 달러로 평가되었고, 2030년까지 연평균 성장률(CAGR) 8.26%로 성장할 것으로 예측됩니다.
기립성 저혈압 또는 자세성 저혈압은 서 있을 때 혈압이 갑자기 떨어져 어지러움, 실신, 피로 등의 증상을 유발하는 질환입니다. 일시적인 경우가 많지만, 특히 고령자나 고혈압 환자의 경우 더 심각한 기저 건강 문제를 나타낼 수도 있습니다. 이 시장은 특히 고령 인구의 인식 증가와 진단 능력 향상에 힘입어 성장하고 있습니다. 동적 혈압 모니터링과 같은 임상 도구 및 진단 프로토콜의 혁신으로 적시에 발견하고 치료할 수 있게 되었습니다. 또한, 특히 개발도상국에서 노인 및 고혈압 환자의 기립성 저혈압 유병률에 대한 관심이 높아지면서 환자 치료 결과를 개선하고 심혈관 위험을 줄이기 위한 효과적인 의약품 요법에 대한 수요가 급증하고 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모(2024년) |
5억 4,226만 달러 |
| 시장 규모(2030년) |
8억 6,608만 달러 |
| CAGR(2025-2030년) |
8.26% |
| 급성장 부문 |
혈액 검사 |
| 최대 시장 |
북미 |
시장 성장 촉진요인
의료 진단의 발전
주요 시장 과제
동반 질환 및 복잡한 환자 프로필
주요 시장 동향
신경인성 기립성 저혈압(nOH) 초점
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 기립성 저혈압 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 제품 유형별(드록시도파, 플루드로코르티손, 인도메타신, 미드드린 염산염, NSAIDs, 피리도스티그민)
- 진단 검사 유형별(혈액 검사, 심전도(ECG), 심장 초음파, 스트레스 검사)
- 최종 사용자별(외래수술센터(ASC), 진단센터, 병원 및 진료소)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 아시아태평양의 기립성 저혈압 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 아시아태평양 : 국가별 분석
제7장 유럽의 기립성 저혈압 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 유럽 : 국가별 분석
제8장 북미의 기립성 저혈압 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 북미 : 국가별 분석
제9장 남미의 기립성 저혈압 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 기립성 저혈압 치료제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 기립성 저혈압 치료제 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
- 업계 내 경쟁
- 신규 진입의 가능성
- 공급자의 힘
- 고객의 힘
- 대체품의 위협
제15장 PESTEL 분석
제16장 경쟁 구도
- Mylan NV
- Upsher-Smith Laboratories, LLC
- Chelsea Therapeutics International, Ltd
- Amgen Inc
- F. Hoffmann-La Roche Ltd
- Apotex Inc
- Pfizer Inc.
- Novartis AG
- H. Lundbeck A/S
- Amneal Pharmaceuticals LLC
제17장 전략적 제안
제18장 기업 소개와 면책사항
HBR
The Global Orthostatic Hypotension Drugs Market was valued at USD 542.26 million in 2024 and is projected to grow at a CAGR of 8.26% through 2030. Orthostatic hypotension, or postural hypotension, involves a sudden drop in blood pressure upon standing, leading to symptoms such as dizziness, fainting, and fatigue. While often transient, the condition can also indicate more serious underlying health issues, especially in older or hypertensive individuals. The market benefits from growing awareness, especially among aging populations, and improved diagnostic capabilities. Innovations in clinical tools and diagnostic protocols-such as dynamic blood pressure monitoring-are facilitating timely detection and treatment. Additionally, rising attention to orthostatic hypotension's prevalence among elderly and hypertensive patients, particularly in developing regions, is spurring demand for effective pharmaceutical therapies aimed at improving patient outcomes and reducing cardiovascular risk.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 542.26 Million |
| Market Size 2030 | USD 866.08 Million |
| CAGR 2025-2030 | 8.26% |
| Fastest Growing Segment | Blood Tests |
| Largest Market | North America |
Key Market Drivers
Advancements in Medical Diagnostics
Medical diagnostics have seen transformative progress, significantly influencing the management of orthostatic hypotension. Advanced molecular tools such as PCR, next-generation sequencing, and gene profiling now enable precise disease detection and characterization. Liquid biopsies offer a non-invasive method for monitoring disease biomarkers, aiding early diagnosis and treatment response. Additionally, point-of-care devices have become more efficient, providing rapid results critical for conditions like blood pressure abnormalities. Imaging advancements-including MRI, CT, and PET-further improve disease visualization and understanding. Artificial intelligence is increasingly applied to analyze complex datasets, supporting diagnostic accuracy and treatment planning. Omics-based biomarker discovery is fostering new diagnostic tests for cardiovascular and neurodegenerative diseases. Notably, a 2024 statement by the American Heart Association emphasized improved diagnosis and management strategies for orthostatic hypotension in hypertensive patients, highlighting the growing clinical focus on this condition and the need for targeted therapies to enhance patient outcomes
Key Market Challenges
Comorbidities and Complex Patient Profiles
Managing orthostatic hypotension becomes increasingly difficult in patients with multiple coexisting conditions such as diabetes, hypertension, or cardiovascular disease. Many of these individuals are on complex medication regimens, increasing the risk of adverse drug interactions and complicating treatment decisions. Polypharmacy often undermines the effectiveness of orthostatic hypotension drugs and raises safety concerns. Customized treatment approaches are necessary to address each patient's unique health profile, which may demand frequent monitoring and ongoing adjustments to therapy. Additionally, patients with overlapping conditions like neurodegenerative disorders face an elevated risk of falls, requiring holistic care strategies. Understanding the complex interplay between various diseases and their impact on blood pressure regulation is vital to delivering effective and safe treatment solutions.
Key Market Trends
Neurogenic Orthostatic Hypotension (nOH) Focus
There is growing clinical and commercial interest in neurogenic orthostatic hypotension (nOH) as a distinct subset of the broader condition. Common in patients with neurological disorders, nOH is increasingly recognized due to improved diagnostic awareness and specialized testing. This subtype, typically involving impaired norepinephrine release, has prompted the development of targeted therapies aimed at improving blood pressure stability. Ongoing clinical trials are evaluating nOH-specific treatments, contributing to a robust pipeline of potential new therapies. Patient advocacy groups and neurological foundations are helping raise awareness and accelerate research in this space. Personalized care strategies are being adopted to address the unique clinical needs of nOH patients. Furthermore, diagnostic advances-such as autonomic function testing-are enhancing accuracy and supporting precision treatment. Pharmaceutical companies are investing in innovative drug classes, including norepinephrine prodrugs and reuptake inhibitors, to meet the specific demands of this growing patient population.
Key Market Players
- Mylan N.V.
- Upsher-Smith Laboratories, LLC
- Chelsea Therapeutics International, Ltd
- Amgen Inc.
- F. Hoffmann-La Roche Ltd
- Apotex Inc
- Pfizer Inc.
- Novartis AG
- H. Lundbeck A/S
- Amneal Pharmaceuticals LLC
Report Scope:
In this report, the Global Orthostatic Hypotension Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Orthostatic Hypotension Drugs Market, By Product:
- Droxidopa
- Fludrocortisone
- Indomethacin
- Midodrine Hydrochloride
- NSAIDs
- Pyridostigmine
Orthostatic Hypotension Drugs Market, By Diagnostics Test Type:
- Blood Tests
- ECG
- Echocardiogram
- Stress Test
Orthostatic Hypotension Drugs Market, By End-User:
- Ambulatory Surgical Centers
- Clinics & Hospitals
- Diagnostic Centers
Orthostatic Hypotension Drugs Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Orthostatic Hypotension Drugs Market.
Available Customizations:
Global Orthostatic Hypotension Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Orthostatic Hypotension Drugs Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Product (Droxidopa, Fludrocortisone, Indomethacin, Midodrine Hydrochloride, NSAIDs, Pyridostigmine)
- 5.2.2. By Diagnostics Test Type (Blood Tests, ECG, Echocardiogram, Stress Test)
- 5.2.3. By End User (Ambulatory Surgical Centers, Diagnostic Centers, Hospitals & Clinics)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map
6. Asia Pacific Orthostatic Hypotension Drugs Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Diagnostics Test Type
- 6.2.3. By End User
- 6.2.4. By Country
- 6.3. Asia Pacific: Country Analysis
- 6.3.1. China Orthostatic Hypotension Drugs Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Product
- 6.3.1.2.2. By Diagnostics Test Type
- 6.3.1.2.3. By End User
- 6.3.2. India Orthostatic Hypotension Drugs Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Product
- 6.3.2.2.2. By Diagnostics Test Type
- 6.3.2.2.3. By End User
- 6.3.3. Australia Orthostatic Hypotension Drugs Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Product
- 6.3.3.2.2. By Diagnostics Test Type
- 6.3.3.2.3. By End User
- 6.3.4. Japan Orthostatic Hypotension Drugs Market Outlook
- 6.3.4.1. Market Size & Forecast
- 6.3.4.2. Market Share & Forecast
- 6.3.4.2.1. By Product
- 6.3.4.2.2. By Diagnostics Test Type
- 6.3.4.2.3. By End User
- 6.3.5. South Korea Orthostatic Hypotension Drugs Market Outlook
- 6.3.5.1. Market Size & Forecast
- 6.3.5.2. Market Share & Forecast
- 6.3.5.2.1. By Product
- 6.3.5.2.2. By Diagnostics Test Type
- 6.3.5.2.3. By End User
7. Europe Orthostatic Hypotension Drugs Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Diagnostics Test Type
- 7.2.3. By End User
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Orthostatic Hypotension Drugs Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product
- 7.3.1.2.2. By Diagnostics Test Type
- 7.3.1.2.3. By End User
- 7.3.2. Germany Orthostatic Hypotension Drugs Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product
- 7.3.2.2.2. By Diagnostics Test Type
- 7.3.2.2.3. By End User
- 7.3.3. Spain Orthostatic Hypotension Drugs Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Product
- 7.3.3.2.2. By Diagnostics Test Type
- 7.3.3.2.3. By End User
- 7.3.4. Italy Orthostatic Hypotension Drugs Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Product
- 7.3.4.2.2. By Diagnostics Test Type
- 7.3.4.2.3. By End User
- 7.3.5. United Kingdom Orthostatic Hypotension Drugs Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Product
- 7.3.5.2.2. By Diagnostics Test Type
- 7.3.5.2.3. By End User
8. North America Orthostatic Hypotension Drugs Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Diagnostics Test Type
- 8.2.3. By End User
- 8.2.4. By Country
- 8.3. North America: Country Analysis
- 8.3.1. United States Orthostatic Hypotension Drugs Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product
- 8.3.1.2.2. By Diagnostics Test Type
- 8.3.1.2.3. By End User
- 8.3.2. Mexico Orthostatic Hypotension Drugs Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product
- 8.3.2.2.2. By Diagnostics Test Type
- 8.3.2.2.3. By End User
- 8.3.3. Canada Orthostatic Hypotension Drugs Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product
- 8.3.3.2.2. By Diagnostics Test Type
- 8.3.3.2.3. By End User
9. South America Orthostatic Hypotension Drugs Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Diagnostics Test Type
- 9.2.3. By End User
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Orthostatic Hypotension Drugs Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product
- 9.3.1.2.2. By Diagnostics Test Type
- 9.3.1.2.3. By End User
- 9.3.2. Argentina Orthostatic Hypotension Drugs Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product
- 9.3.2.2.2. By Diagnostics Test Type
- 9.3.2.2.3. By End User
- 9.3.3. Colombia Orthostatic Hypotension Drugs Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product
- 9.3.3.2.2. By Diagnostics Test Type
- 9.3.3.2.3. By End User
10. Middle East and Africa Orthostatic Hypotension Drugs Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Diagnostics Test Type
- 10.2.3. By End User
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Orthostatic Hypotension Drugs Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product
- 10.3.1.2.2. By Diagnostics Test Type
- 10.3.1.2.3. By End User
- 10.3.2. Saudi Arabia Orthostatic Hypotension Drugs Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product
- 10.3.2.2.2. By Diagnostics Test Type
- 10.3.2.2.3. By End User
- 10.3.3. UAE Orthostatic Hypotension Drugs Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product
- 10.3.3.2.2. By Diagnostics Test Type
- 10.3.3.2.3. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Orthostatic Hypotension Drugs Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
- 16.1. Mylan N.V.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
- 16.2. Upsher-Smith Laboratories, LLC
- 16.3. Chelsea Therapeutics International, Ltd
- 16.4. Amgen Inc
- 16.5. F. Hoffmann-La Roche Ltd
- 16.6. Apotex Inc
- 16.7. Pfizer Inc.
- 16.8. Novartis AG
- 16.9. H. Lundbeck A/S
- 16.10. Amneal Pharmaceuticals LLC
17. Strategic Recommendations
18. About Us & Disclaimer
